Profile data is unavailable for this security.
About the company
Celularity Inc. is a clinical-stage biotechnology company. The Company is engaged in developing off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through three business segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapy product candidates include T cells engineered with a chimeric antigen receptor (CAR), natural killer, cells, mesenchymal-like adherent stromal cells (MLASCs), and exosomes. These therapeutic candidates target indications across cancer, infectious and degenerative diseases. Its cell therapeutic programs include CYCART-19, CYCART-201, CYNK-001, CYNK-301, CYNK-302, APPL-001, and pEXO-001. CYCART-19 is a placental-derived CAR-T cell therapy, in development for the treatment of B-cell malignancies, initially targeting the cluster of differentiation 19. pExo-001 is developed for the treatment of osteoarthritis. APPL-001 is developed for the treatment of Crohn’s disease.
- Revenue in USD (TTM)14.79m
- Net income in USD-181.41m
- Incorporated2018
- Employees225.00
- LocationCelularity Inc170 Park AveFLORHAM PARK 07932United StatesUSA
- Phone+1 (908) 768-2170
- Fax+1 (302) 636-5454
- Websitehttps://celularity.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioqual Inc | 62.86m | 957.02k | 64.85m | 108.00 | 67.76 | 1.67 | 18.49 | 1.03 | 1.07 | 1.07 | 70.28 | 43.41 | 1.04 | -- | 2.99 | -- | 1.59 | 8.14 | 1.80 | 9.52 | 14.13 | 19.36 | 1.52 | 7.13 | -- | -- | 0.00 | 21.43 | -5.27 | 11.79 | -84.12 | -25.26 | 1.60 | 10.76 |
| Regencell Bioscience Holdings Ltd | 0.00 | -7.45m | 65.85m | 12.00 | -- | 3.86 | -- | -- | -0.5863 | -0.5863 | 0.00 | 1.31 | 0.00 | -- | -- | 0.00 | -82.73 | -- | -113.11 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.15 | -- | -- | -- |
| Rallybio Corp | 0.00 | -76.28m | 65.90m | 43.00 | -- | 0.6743 | -- | -- | -1.88 | -1.88 | 0.00 | 2.36 | 0.00 | -- | -- | 0.00 | -58.30 | -- | -62.32 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.87 | -- | -- | -- |
| Turnstone Biologics Corp | 0.00 | -74.92m | 66.38m | 82.00 | -- | 0.8296 | -- | -- | -3.53 | -3.53 | 0.00 | 3.46 | 0.00 | -- | -- | 0.00 | -80.25 | -- | -94.45 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -73.66 | -- | -78.05 | -- | -- | -- |
| Aeon Biopharma Inc | 0.00 | -137.01m | 66.51m | 10.00 | -- | -- | -- | -- | -3.68 | -3.68 | 0.00 | -5.20 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -4.14 | -- | -- | -- | -- | 30.30 | -- | -- | -- |
| AN2 Therapeutics Inc | 0.00 | -66.03m | 66.52m | 41.00 | -- | 0.6012 | -- | -- | -2.59 | -2.59 | 0.00 | 3.71 | 0.00 | -- | -- | 0.00 | -62.19 | -- | -68.38 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -51.33 | -- | -- | -- |
| Immix Biopharma Inc | 0.00 | -18.21m | 66.56m | 14.00 | -- | 2.38 | -- | -- | -0.9263 | -0.9263 | 0.00 | 1.06 | 0.00 | -- | -- | 0.00 | -77.50 | -- | -90.46 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -87.44 | -- | -- | -- |
| enVVeno Medical Corp | 0.00 | -22.12m | 66.65m | 31.00 | -- | 1.57 | -- | -- | -1.70 | -1.70 | 0.00 | 3.18 | 0.00 | -- | -- | 0.00 | -54.31 | -58.43 | -56.14 | -62.76 | -- | -- | -- | -260,799.30 | -- | -- | 0.00 | -- | -- | -- | 4.67 | -- | 21.58 | -- |
| Medicinova Inc | 1.00m | -8.41m | 67.19m | 13.00 | -- | 1.12 | -- | 67.19 | -0.1714 | -0.1714 | 0.0204 | 1.22 | 0.0149 | -- | -- | 76,923.08 | -12.55 | -15.36 | -13.06 | -15.90 | -- | -- | -840.85 | -1,182.54 | -- | -- | 0.00 | -- | -- | -- | 39.08 | -- | 15.87 | -- |
| Ikena Oncology Inc | 3.85m | -70.09m | 67.56m | 34.00 | -- | 0.4349 | -- | 17.56 | -1.58 | -1.58 | 0.0861 | 3.22 | 0.0237 | -- | -- | 89,488.38 | -43.11 | -29.72 | -46.56 | -34.62 | -- | -- | -1,821.54 | -294.90 | -- | -- | 0.00 | -- | -41.35 | 56.05 | 0.8711 | -- | 6.30 | -- |
| CEL-SCI Corp | 0.00 | -29.95m | 68.24m | 43.00 | -- | 4.76 | -- | -- | -0.6304 | -0.6304 | 0.00 | 0.2645 | 0.00 | -- | -- | -- | -87.78 | -70.19 | -103.56 | -78.31 | -- | -- | -- | -15,434.15 | 1.18 | -39.26 | 0.4319 | -- | -- | -- | 13.99 | -- | 223.59 | -- |
| Celularity Inc | 14.79m | -181.41m | 68.40m | 225.00 | -- | 2.01 | -- | 4.63 | -10.51 | -10.51 | 0.8376 | 1.56 | 0.0498 | 2.29 | 2.03 | 65,724.45 | -61.05 | -- | -82.37 | -- | 21.19 | -- | -1,226.72 | -- | 0.1366 | 18.40 | 0.5365 | -- | -15.75 | -- | 114.18 | -- | -- | -- |
| Intensity Therapeutics Inc | 0.00 | -15.13m | 68.56m | 5.00 | -- | 7.05 | -- | -- | -1.10 | -1.10 | 0.00 | 0.709 | 0.00 | -- | -- | 0.00 | -206.66 | -- | -696.72 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -56.45 | -- | -- | -- |
| Landos Biopharma Inc | 0.00 | -24.80m | 69.42m | 19.00 | -- | 2.99 | -- | -- | -3.99 | -3.99 | 0.00 | 7.43 | 0.00 | -- | -- | 0.00 | -61.17 | -59.84 | -70.67 | -72.15 | -- | -- | -- | -795.80 | -- | -594.02 | 0.00 | -- | -- | -- | 44.15 | -- | -- | -- |
| LAVA Therapeutics NV | 6.77m | -41.97m | 70.98m | 37.00 | -- | 1.39 | -- | 10.49 | -1.58 | -1.58 | 0.2532 | 1.95 | 0.0552 | -- | 2.87 | 182,946.00 | -34.25 | -- | -40.31 | -- | 48.56 | -- | -620.09 | -- | -- | -- | 0.1098 | -- | -65.09 | -- | -31.55 | -- | -- | -- |
Data as of May 21 2024. Currency figures normalised to Celularity Inc's reporting currency: US Dollar USD
13.90%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Starr Investment Holdings LLCas of 30 Sep 2023 | 1.53m | 7.02% |
| C.V. Starr & Co., Inc.as of 30 Sep 2023 | 764.07k | 3.51% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 382.60k | 1.76% |
| Geode Capital Management LLCas of 31 Mar 2024 | 134.64k | 0.62% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 76.36k | 0.35% |
| Cresset Asset Management LLCas of 31 Mar 2024 | 35.00k | 0.16% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 29.77k | 0.14% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 27.35k | 0.13% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 24.93k | 0.11% |
| HB Wealth Management LLC (GA)as of 31 Mar 2024 | 24.00k | 0.11% |
More ▼
Data from 30 Sep 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
